NCT02598661 2026-01-05
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Geron Corporation
Phase 2/3 Active not recruiting
Geron Corporation
Novartis
Shanghai Junshi Bioscience Co., Ltd.
Celgene
Celgene
BeiGene
Karyopharm Therapeutics Inc
Amgen
Novartis
Amgen